NCT03341806View on ClinicalTrials.gov

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

October 13, 2021

Study Completion Date

October 13, 2021

Conditions
GlioblastomaGBM
Interventions
DRUG

Avelumab

Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles

COMBINATION_PRODUCT

MRI-guided LITT therapy

(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03341806 - Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter